Amgen (AMGN) Stock Forecast & Price Target

$321.22

-3.14 (-0.97%)

(As of 11:27 AM ET)

Amgen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 22 Analyst Ratings

Based on 22 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 11 have given a hold rating, and 11 have given a buy rating for AMGN.

Consensus Price Target

$326.89
1.77% Upside

High Forecast	$381.00
Average Forecast	$326.89
Low Forecast	$235.00

According to the 22 analysts' twelve-month price targets for Amgen, the average price target is $326.89. The highest price target for AMGN is $381.00, while the lowest price target for AMGN is $235.00. The average price target represents a forecasted upside of 1.77% from the current price of $321.22.

Type	Current Forecast 9/7/23 to 9/6/24	1 Month Ago 8/8/23 to 8/7/24	3 Months Ago 6/9/23 to 6/8/24	1 Year Ago 9/7/22 to 9/7/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	7 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$326.89	$326.89	$305.65	$259.53
Forecasted Upside	1.77% Upside	7.92% Upside	5.59% Upside	4.82% Upside

Get Amgen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Apple to take the AI industry by storm on September 10

Apple is often late to embrace new technologies, yet they almost always go on to crush their competition... But I believe they're finally set to roll out their first ever AI device by September 10...

Get their details here.

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.76	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	0.78% Upside	1,925.34% Upside	10.14% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/7/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$360.00 ➝ $381.00	+21.92%
8/7/2024	Bank of America 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$325.00 ➝ $330.00	+6.40%
8/7/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Reiterated Rating	Hold ➝ Hold	$310.00 ➝ $305.00	-1.66%
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
8/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$375.00 ➝ $380.00	+22.79%
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$332.00 ➝ $362.00	+15.03%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$320.00 ➝ $335.00	+1.84%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$310.00 ➝ $303.00	-6.67%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$223.00 ➝ $235.00	-23.53%
5/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$284.00 ➝ $307.00	-1.65%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
5/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$230.00 ➝ $300.00	+7.76%
5/3/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/12/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$320.00	+19.35%
3/28/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
2/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$324.00 ➝ $318.00	+0.61%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%
4/28/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$293.00 ➝ $288.00	+19.83%
2/2/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$282.00 ➝ $267.00	+8.36%
2/1/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$307.00 ➝ $289.00	+14.50%
9/13/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform	$185.00	-21.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:03 PM ET.

AMGN Forecast - Frequently Asked Questions

What is Amgen's forecast for 2024?: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $326.89, with a high forecast of $381.00 and a low forecast of $235.00.
Should I buy or sell Amgen stock right now?: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 11 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
Does Amgen's stock price have much upside?: According to analysts, Amgen's stock has a predicted upside of 7.92% based on their 12-month stock forecasts.
Has Amgen been downgraded by Wall Street analysts recently?: Over the previous 90 days, Amgen's stock had 1 downgrade by analysts.
What analysts cover Amgen?: Amgen has been rated by research analysts at Argus, Bank of America, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Royal Bank of Canada, TD Cowen, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Amgen more than its competitors?: Analysts like Amgen less than other "medical" companies. The consensus rating score for Amgen is 2.50 while the average consensus rating score for "medical" companies is 2.76. Learn more on how AMGN compares to other companies.